Shopping Cart
- Remove All
- Your shopping cart is currently empty
Drozitumab (PRO 95780) is a fully humanized antibody targeting the death receptor DR5 that shows anti-tumor activity against rhabdomyosarcoma, binds to the death receptor DR5 and induces apoptosis, and can be used in the study of triple-negative breast cancer.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $197 | In Stock | |
5 mg | $596 | In Stock | |
10 mg | $959 | In Stock | |
25 mg | $1,420 | In Stock | |
50 mg | $1,920 | In Stock |
Description | Drozitumab (PRO 95780) is a fully humanized antibody targeting the death receptor DR5 that shows anti-tumor activity against rhabdomyosarcoma, binds to the death receptor DR5 and induces apoptosis, and can be used in the study of triple-negative breast cancer. |
In vitro | Drozitumab is able to target and remove cancer stem cells (CSCs), thereby stopping tumor growth and potentially shrinking or even regressing pancreatic tumors. [3] Drozitumab caused apoptosis in mesenchymal TNBC cell lines, but did not show the same effect in other subtypes of breast cancer cell lines. [1] |
Alias | rhuMAb-DR 5, RG7425, RG 7425, PRO95780, PRO 95780, Anti-Human DR5 Recombinant Antibody |
Molecular Weight | 143.1 (kDa) |
Cas No. | 912628-39-8 |
Storage | store at low temperature | store at -20°C | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.